[en] BACKGROUND & AIMS: Crohn's disease (CD) patients included in the Tailored Treatment With Infliximab for Active Crohn's Disease (TAILORIX) trial started infliximab in combination with an immunosuppressant for 1 year. The aim of the present study was to determine the long-term disease course beyond the study period. METHODS: We compared the outcomes of patients who did or did not reach the primary end point of the TAILORIX trial, defined as sustained corticosteroid-free clinical remission from weeks 22 through 54, with no ulcers on ileocolonoscopy at week 54. The primary outcome of this follow-up study was the progression-free survival of CD defined by anal or major abdominal surgery, CD-related hospitalization, or the need for a new systemic CD treatment. RESULTS: The 95 patients (median disease duration, 4.5 mo; interquartile range, 1.0-56.6 mo) analyzed, including 45 (47%) who achieved the primary end point, were followed up for a median duration of 64.2 months (interquartile range, 57.6-69.9 mo) after the end of the study period. There was no significant difference in CD progression-free survival at 1, 3, and 5 years between patients who achieved the TAILORIX primary end point and patients who did not (P = .64). No difference was observed between both groups for each component of CD progression: anal surgery, major abdominal surgery, CD-related hospitalization, or the need for a new systemic CD treatment. CONCLUSIONS: Achieving a sustained clinical remission off steroids with complete endoscopic remission in this cohort of 95 patients with early CD was not associated with less disease progression. Prospective trials to define the therapeutic goals that change the natural history of CD and prevent complications are needed.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Laharie, David; Centre Hospitalier Universitaire de Bordeaux, Hôpital Haut-Lévêque, Service
D'Haens, Geert; Hepato-Gastroenterology Department, Amsterdam University Medical Centers,
Nachury, Maria; Hepato-Gastroenterology Department, Claude Huriez Hospital, University of Lille,
Lambrecht, Guy; Gastroenterology Unit, Damiaan Hospital, Oostende, Belgium.
Bossuyt, Peter; Imelda Gastronintestinal Clinical Research Center, Department of
Pariente, B., Cosnes, J., Danese, S., et al. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis 17 (2011), 1415–1422.
Peyrin-Biroulet, L., Loftus, E.V., Colombel, J.-F., et al. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 105 (2010), 289–297.
Allen, P.B., Peyrin-Biroulet, L., Moving towards disease modification in inflammatory bowel disease therapy. Curr Opin Gastroenterol 29 (2013), 397–404.
Panaccione, R., Colombel, J.-F., Louis, E., et al. Evolving definitions of remission in Crohn's disease. Inflamm Bowel Dis 19 (2013), 1645–1653.
Turner, D., Ricciuto, A., Lewis, A., et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 160 (2021), 1570–1583.
Berg, D.R., Colombel, J.-F., Ungaro, R., The role of early biologic therapy in inflammatory bowel disease. Inflamm Bowel Dis 25 (2019), 1896–1905.
Shah, S.C., Colombel, J.-F., Sands, B.E., et al. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease. Aliment Pharmacol Ther 43 (2016), 317–333.
Yzet, C., Diouf, M., Le Mouel, J.-P., et al. Complete endoscopic healing associated with better outcomes than partial endoscopic healing in patients with Crohn's disease. Clin Gastroenterol Hepatol 18 (2020), 2256–2261.
Ungaro, R.C., Yzet, C., Bossuyt, P., et al. Deep remission at 1 year prevents progression of early Crohn's disease. Gastroenterology 159 (2020), 139–147.
Baert, F., Moortgat, L., Van Assche, G., et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 138 (2010), 463–468.
Björkesten, C.-G., Nieminen, U., Sipponen, T., et al. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scand J Gastroenterol 48 (2013), 543–551.
Frøslie, K.F., Jahnsen, J., Moum, B.A., et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133 (2007), 412–422.
D'Haens, G., Vermeire, S., Lambrecht, G., et al. Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn's disease. Gastroenterology 154 (2018), 1343–1351.
Peyrin-Biroulet, L., Sandborn, W., Sands, B.E., et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110 (2015), 1324–1338.
Daperno, M., D'Haens, G., Van Assche, G., et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 60 (2004), 505–512.
Khanna, R., Bouguen, G., Feagan, B.G., et al. A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial design. Inflamm Bowel Dis 20 (2014), 1850–1861.
Schnitzler, F., Fidder, H., Ferrante, M., et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 15 (2009), 1295–1301.
Tsai, L., Ma, C., Dulai, P.S., et al. Contemporary risk of surgery in patients with ulcerative colitis and Crohn's disease: a meta-analysis of population-based cohorts. Clin Gastroenterol Hepatol 19 (2021), 2031–2045.e11.
Kalman, T.D., Everhov, Å.H., Nordenvall, C., et al. Decrease in primary but not in secondary abdominal surgery for Crohn's disease: nationwide cohort study, 1990-2014. Br J Surg 107 (2020), 1529–1538.
Kugathasan, S., Denson, L.A., Walters, T.D., et al. Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study. Lancet 389 (2017), 1710–1718.
Khanna, R., Bressler, B., Levesque, B.G., et al. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet 386 (2015), 1825–1834.
Le Berre, C., Peyrin-Biroulet, L., SPIRIT-IOIBD Study Group. selecting endpoints for disease-modification trials in inflammatory bowel disease: the SPIRIT consensus from the IOIBD. Gastroenterology 160 (2021), 1452–1460.
Silverberg, M.S., Satsangi, J., Ahmad, T., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. J Can Gastroenterol 19:Suppl A (2005), 5A–36A.
